You fly in, you present, you charm the room. Heads nod. The technical team likes your data. The business unit agrees that the fit is strong. Someone says, “Let’s stay in touch.”
Then nothing.
You follow up for months, sometimes years. You receive kind replies, seasonal greetings, maybe a small pilot. Revenue, however, stays stubbornly close to zero. Your board wonders what is wrong with Japan. Your team wonders what is wrong with your local partner. Quietly, some leaders start to suspect that Japanese companies simply do not want foreign suppliers.
The uncomfortable truth: to many Japanese organisations, your company looks like a ghost. You are visible on Zoom, your deck is impressive, your tech is credible, yet in the Japanese business world you have almost no tangible presence. In a culture that prizes brick-and-mortar, long-term bonds and risk avoidance, a “remote-first” overseas vendor without a real footprint is treated as a corporate yūrei: something that is here one day and gone the next.
This blog explains why that “ghost” perception quietly blocks orders even when you have strong meetings. Let’s also dive into a concrete general plan to materialise business in Japan, compress the infamous five-year valley, and turn polite interest into POs and enduring partnerships.
Part 1 – From Courted to Ghosted: What Japanese Clients Really See
If you have spent years in courteous meetings yet still ask yourself why Japanese customers don’t buy from you, the answer usually sits in how your organisation appears inside the Japanese risk calculus. From your side, the story sounds straightforward:
You have a proven service, product or platform.
You can show global references and robust data.
Your pricing is competitive.
The Japanese team says they are “very interested”.
From their side, a very different movie plays. You see, in Japanese business culture, trust splits into two different but crucial layers:
Shinrai – confidence that your product works.
Shinyo – trust that you as a corporate actor will stay, support, compensate and behave honourably over many years.
Western sales playbooks concentrate almost entirely on Shinrai. You optimise the demo, the benchmark, the ROI slide. You invest in pre-sales engineers and KOL quotes. All of this builds confidence in your solution. It does not resolve the more fundamental doubt:
“When our internal sponsor has rotated twice and the first serious problem hits, will this company still be here to face us across the table?”
When you operate from overseas, route contracts through a foreign entity, rely on a distributor with a Gmail address or have no proper office that a client can visit, you fail the Shinyo test. In practice, the Japanese side sees:
A vendor with no obvious physical place to take immediate responsibility if something malfunctions.
A company that seems easy to shut down or reassign in the next global restructuring.
An organisation that does not share the same long-term social fabric as domestic partners.
That perception explains why pilots stall, why framework agreements never arrive and why, in the internal decision document, your name silently drops off the shortlist.
You are not rejected because the proposal is weak. You are ignored because the entity offering it does not feel real enough to carry the risk for the long term.
Part 2 – The Slow Clock: Why “Five Years” Is a Feature, Not a Bug
Many executives I’ve had the privilege of dining with recognise this pattern: for the first two years, Japan feels exciting. There are frequent visits, conferences, pilots, NDAs. Then progress slows. Revenue barely moves. Somewhere around year four or five, a step-change happens and traction finally manifests. …if the company is still present and has acted serious throughout the journey.
Understanding this different clock is essential if you want to change why Japanese customers don’t buy quickly from you.
A simplified version of the timeline:
Years 1–2 – Greeting phase
You appear on the radar. People take meetings from curiosity and benchmarking motives. Large clients treat you as “future options”. Real contracts are rare. The main question in this phase: Will they vanish when HQ changes strategy?Years 3–4 – Probation phase
If you remain active, some organisations start limited proofs of concept. These are not only technical tests. They check how your support behaves, how you respond to issues, how your local representative handles internal politics and how you cope with requests that never appear in Western RFPs.Year 5 and beyond – Trust horizon
Surviving that long signals staying power. This reduces the perceived “flight-risk discount”. Banks, senior hires and large conservative clients slowly recalibrate you from “interesting foreign vendor” to “member of the ecosystem”.
This pattern feels frustrating from a Western perspective that expects traction within 6 months. In Japan, however, it reflects rational risk management:
Supply chains are dense and sticky. A failed vendor relationship creates loss of face internally, and operational damage.
Past experiences include high-profile foreign exits (suppliers, carriers, platforms) still colours judgement.
Long-lived firms dominate many sectors, so a young foreign company looks like a transitory experiment.
Crucially, a remote-first approach lengthens this clock. If you want to shorten the timeline, you must change the perceived denominator of risk, not simply push harder on top-line sales activity.
Part 3 – How Best-Practice Western Sales Makes Things Worse
Many international teams assume that if they refine their sales discipline, Japan will “open up”. They train reps on Challenger, SPIN, MEDDIC and creative closing tactics. Paradoxically, this usually increase the difficulties of getting to the coveted POs. Here is whst you need to learn!
Challenger behaviour looks like aggression
The Challenger method encourages reps to “teach, tailor and take control”. In many Western markets, a salesperson who argues with the client and reframes their thinking appears confident and expert. In Japan, that person can look presumptuous and disrespectful:
“Teaching” a senior client implies that they failed to think about their own business.
“Taking control” of the meeting disrupts the ritual pattern that maintains harmony.
Creating “constructive tension” simply produces discomfort that everyone wants to dissolve. The polite Japanese way to dissolve it is to stop returning calls and emails.
SPIN questions collide with loss of face
SPIN Selling asks the rep to dig into explicit problems and implications. That makes sense where transparency about internal issues is normal. Inside many Japanese organisations, acknowledging serious problems to an outsider causes loss of face for the whole department or company.
Many answers remain vague. The real problems stay hidden inside the company, discussed over late-night drinks with colleagues, never in front of a foreign vendor on Teams.
“Always be closing” triggers alarm bells
Urgency is another Western virtue that turns toxic in Japan:
Quarter-end pressure signals that your priority sits with HQ, not with your client’s risk profile.
Aggressive discount deadlines suggest financial instability or strategic confusion.
Attempts to rush the Ringisho (internal approval document) risk embarrassing your internal sponsor, who must answer for all of your mis-steps.
The result is never a faster decision or a shortened sales cycle. The result is a quiet internal assessment that you do not understand how serious all undertaken commitments are to them.
Remote selling kills “air reading”
Japan is a high-context society where much of the real signal sits between the words: small pauses, glances, how people sit when your slide appears. On video calls, that layer disappears or blurs. You hear “We will consider it” and interpret it as genuine interest. Your local contact may hear exactly the same words and read the air as “polite rejection”.
If your entire go-to-market relies on remote meetings and imported playbooks, you not only miss that signal. You also project a style that feels risky, pushy or simply alien. No one wants to sign a multi-year agreement with a vendor that lives on a different planet.
Part 4 – Borrow Credibility: Piggyback on a Senior Consultant to Lead You to Success in Japan
The quickest way to shift why Japanese customers don’t buy from you beyond pilots is to borrow trust. Do not rush to establish a subsidiary, a shiny office or a headcount plan that outpaces learning. The fastest shift comes from borrowing a living, breathing presence that already carries trust, context and authority with Japanese pharma.
That presence can look very much like a senior business development consultant who builds your foundation and creates traction. Derisking, learning and preparing the soil before you bring in the cavallery.
Why a consultant can feel more real than your future subsidiary
From the client’s perspective, risk attaches to people they can see, call and meet. A carefully chosen consultant can feel far more tangible than a legally perfect but inexperienced subsidiary.
When a Japanese pharma team meets a consultant who:
knows their therapeutic areas and understands the science fluently
respects their internal approval steps, politics and time horizons
already meets peers at conferences, study groups and industry associations
they gain something more important than a corporate registration document. They gain a person who will still be there the next time they need to discuss an unexpected manufacturing issue, a safety concern from PMS data or a new biomarker strategy.
In that light, a skilled professional with the right background becomes your first risk absorber and your first reassurance mechanism.
Scientific depth is a sales prerequisite, not a nice-to-have asset
In pharma, medtech and diagnostics, scientific understanding is not decoration. It decides whether your counterpart in R&D or medical affairs feels safe to attach their name to your solution.
A consultant with real technical grounding can:
challenge trial designs or endpoints in a way that increases respect rather than irritation
translate your global clinical package into what Japanese KOLs expect to see
manage and decipher formal meetings and lead informal meetings to fruition
speak with credibility to safety officers, QA, PV teams and statisticians, not just commercial staff
This scientific fluency changes the entire tenor of client interactions. Discussions move away from generic “innovation” talk and slide-heavy product pitches. Instead, meetings become collaborative and the business relationships deepen. That is precisely the environment where Japanese teams begin to imagine you as a long-term partner rather than a vendor.
Salesmanship that respects Japanese process
Scientific strength alone does not convert interest into contracts. It must sit inside a sales approach that fits Japanese norms. This is what experience looks like in this field:
pace conversations so internal Nemawashi can happen without stress
prepare your materials for Ringisho-style internal documents with the right balance of data, risk framing and precedent
coach your global team on what not to say or do
spot which comment in a meeting is a real objection, which is a face-saving signal, which is a quietly coded “yes”
Instead of pushing for premature “commitments”, this kind of salesmanship gradually builds safety for your internal sponsor. They feel supported as professionals in their own environment. That feeling is often the invisible line between another polite meeting and a real decision.
Acting as your rehearsal stage for future scale-up
When you later decide to build a formal Japanese organisation, you want that team to arrive with a refined playbook. A seasoned consultant serves as your rehearsal stage and can make all the difference. Over the first phases of market engagement, here are some key objectives I help help my clients gain insights around:
which companies and departments in Japanese pharma resonate most strongly with your data and value story
where your standard contracts, pricing structures or SLA language clash with Japanese expectations
which pain points and proofs of concept carry the highest signalling value with key accounts
how your communication rhythm should look across HQ, local presence and client
Those lessons become the foundation for your future Country Manager, medical lead and sales team. Instead of “learning on the client”, your new hires inherit a vetted approach and a network that already sees your company as a known quantity. In other words, a high-calibre consultant with the right network, scientific strength and commercial maturity is not a temporary fix. That person is your first genuine presence in Japan. He or she is the bridge between being a ghost on a screen and becoming a trusted participant in the country’s pharma ecosystem.
Part 5 – Traction First, Infrastructure Later: The Consultant as Your First “Japanese Entity”
Once you recognise that trust, context and risk perception sit at the core of why Japanese customers don’t buy from you yet at scale, the question changes. Instead of asking “How fast can we open a subsidiary?”, the more productive question becomes: “Who can give us real presence, insight and access before we deploy heavy assets?” Sales experience and a useful network in Japan functions as your first, best and pragmatic “entity”.
Why you send a consultant before the cavallery
Building a full organisation from day one sounds decisive. For Japan, it often produces expensive learning curves:
A newly hired Country Manager must build relationships from zero.
Your first local hires spend years understanding unwritten rules inside the Japanese lifescience ecosystems.
The organisation experiments with communication styles, pricing logic and internal approval paths through trial and error.
During that period, headquarters expects revenue. Local teams, under pressure, push too hard or misread signals. Internal sponsors at Japanese clients see a vendor that behaves like a freshman student in a post graduate seminar. Contracts stay small or do not appear, much less reappear. If who have someone who already understands the pharma sector, reads your data, grasps all the cultural nuances and understands the corporate decision-making, things will go smoothly. If not, you may end up short-circuiting your deal flows.
The right consultant must behave like a Japan GM
A high-calibre achiever in this space is not a “door opener” who simply introduces you to contacts. The role is closer to a fractional Country Manager with a lab notebook in one hand and a sales pipeline in the other:
Scientific competence – ability to discuss mode of action, study design, endpoints, assay performance, real-world evidence and safety signals with medical and development teams without losing credibility.
Commercial literacy – understanding of how Japanese pharma assesses risk-adjusted NPV, portfolio fit, licensing terms, service SLAs and co-promotion options.
Network density – relationships across R&D, business development, marketing, medical affairs and procurement, which matters more than a few big-name business cards.
Cultural translation – capacity to decode what Japanese stakeholders really signal when they say “interesting” or “difficult”, and to translate your internal expectations into forms that your counterparts can accept.
This type of consultant helps you behave like a seasoned local participant long before you have a full legal structure and headcount.
The best first 12–24 months with aligned expectations
With an embedded expert at your side, the early phases in Japan look different:
Target selection improves
Instead of chasing every large name, you prioritise clients where your value proposition fits current strategic gaps, regulatory pressure or portfolio rebalancing. Time wasted on low-probability prospects drops sharply.Conversations deepen quickly
Technical calls move from “product pitches” to peer-level discussions on study design, biomarker strategy, patient stratification or manufacturing robustness. Internal scientists at Japanese companies relax because they are speaking with someone who speaks their language.Internal champions are nurtured correctly
Your consultant guides how you support early enthusiasts so they gain status, not risk, when they sponsor your project. That may involve careful choice of pilot size, data-sharing cadence and communication pattern with their superiors.Feedback becomes brutally useful
Instead of polite emails, you receive structured, culturally decoded feedback: which part of your proposal triggers internal anxiety, which data package feels thin, which legal clause collides with standard Japanese expectations.
The outcome is straightforward: real traction, better-shaped pilots and early revenue without committing prematurely to large fixed costs in a market your organisation still does not fully understand.
Preparing your future Japanese operation to succeed
A strong consultant does not intend to stay forever as the sole presence. The role is to prepare the ground so that when you bring in the cavallery, they charge into a space that already understands you and welcomes your presence.
When you finally establish a subsidiary or sales office, it no longer arrives as a ghost. It appears as the natural next step of a relationship network that already exists and a market narrative that already has traction. Your consultant has, in effect, taught your future Japanese operation how to behave long before it takes its first official breath.
We have been supporting cross-border commercialization in Japan for almost 20 years and are eager to explore your needs and expectations regarding commercialisation in Japan. You are warmly welcome to book a meeting directly here https://www.calendly.com/biosector or send an email to info@biosector.jp
Comments are closed